Parkinson's disease and related neurodegenerative conditions may have found a new therapeutic target in transglutaminase 2, an enzyme whose cross-linking activity appears central to the formation of toxic protein aggregates that define these disorders. This finding could reshape treatment approaches for millions facing synucleinopathies worldwide.
The research demonstrates that TG2's enzymatic cross-linking function specifically promotes α-synuclein aggregation into the pathological clumps characteristic of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Using synucleinopathy models, investigators showed that blocking TG2's cross-linking activity reduced pathological protein accumulation, while the enzyme's other cellular functions remained intact. This specificity suggests TG2 cross-linking represents a direct pathological mechanism rather than a secondary consequence of neurodegeneration.
This mechanistic insight addresses a critical gap in synucleinopathy research, where α-synuclein aggregation has long been observed but the precise molecular drivers remained unclear. TG2 inhibitors already exist in pharmaceutical pipelines for other conditions, potentially accelerating therapeutic development. However, TG2 serves multiple cellular functions beyond pathological cross-linking, including roles in cell adhesion and wound healing, making selective inhibition crucial. The challenge lies in developing compounds that block disease-driving cross-linking while preserving beneficial TG2 activities. Additionally, these findings emerge from laboratory models, requiring validation in human tissue and clinical trials to confirm therapeutic relevance. If confirmed, targeting TG2 cross-linking could offer the first disease-modifying treatment for synucleinopathies, moving beyond symptom management toward preventing the underlying protein pathology.